Prazosin

Prazosin is a quinazoline-derived drug that selectively blocks alpha-1 adrenergic receptors, the receptors that noradrenaline and adrenaline use to make blood vessels and other smooth muscle contract ^[1]. As one of the first selective alpha-1 antagonists, it lowers vascular tone and therefore blood pressure, which was the basis of its original role as an antihypertensive ^[1].

The compound was patented in the 1960s and entered medical use in 1974 under the brand name Minipress. It is now an inexpensive generic medicine that remains in regular use, although for uncomplicated high blood pressure it is usually considered a later-line option rather than a first choice.

Beyond hypertension, prazosin is used to relax smooth muscle in the prostate and bladder neck, easing urinary flow in benign prostatic enlargement, and it has an off-label role in Raynaud's phenomenon ^[1]. It is perhaps most discussed for post-traumatic stress disorder, where it is used to target trauma-related nightmares. The evidence here is genuinely mixed: a systematic review and meta-analysis of randomised trials found that prazosin improved nightmares, while not clearly helping overall PTSD symptoms or general sleep quality ^[2], whereas a large multicentre trial in military veterans found no benefit over placebo for distressing dreams or sleep ^[3]. Reviews of mental-health prescribing continue to treat it as a mechanism-based option for selected patients ^[4], and its actions on stress hormones have also prompted laboratory interest in catecholamine-driven cytokine release syndrome ^[5].

Prazosin is a prescription medicine taken as oral capsules or tablets. A well-known feature is the first-dose phenomenon, in which the initial dose can cause a pronounced fall in blood pressure with dizziness or even fainting, so treatment is typically started at a low bedtime dose and increased gradually ^[1].

Prazosin is prescription only. Its signature risk is the first dose phenomenon; a sharp fall in standing blood pressure that can cause dizziness or fainting, so the first dose is small and taken at bedtime. Ongoing effects include lightheadedness, headache, palpitations, stuffy nose, tiredness and ankle swelling, and rarely a prolonged painful erection. People heading for cataract surgery should warn their eye surgeon because alpha blockers can cause floppy iris syndrome. Combining it with erectile dysfunction drugs such as sildenafil or with other blood pressure lowering medicines can stack the drop in pressure.

Prazosin blocks alpha-1 adrenoceptors, and its interactions are dominated by additive vasodilation stacked on a drug that already causes first-dose syncope.

PDE5 inhibitors are the sharpest of these. Sildenafil, tadalafil and vardenafil are vasodilators in their own right, and combined with alpha-1 blockade they produce symptomatic hypotension and syncope; the risk is highest within a few hours of either drug and while prazosin is being started or titrated. Other antihypertensives, nitrates and alcohol do the same thing less abruptly. Calcium channel blockers deserve separate mention because verapamil raises prazosin plasma concentrations as well as adding its own vasodilation, so the two effects compound.

In the opposite direction, NSAIDs promote sodium retention and blunt the antihypertensive effect. Beta-blockers do not change prazosin levels, but they remove the reflex tachycardia that normally defends blood pressure when you stand up, which makes the orthostatic drop worse.

Checking a whole stack? Run it through interactions + stacks.

Prazosin was developed by Pfizer and introduced in the 1970s as one of the first selective alpha-1 adrenergic receptor antagonists, a quinazoline-class agent designed to lower blood pressure by relaxing vascular smooth muscle without the reflex tachycardia seen with non-selective blockers. Marketed under the brand name Minipress, it became an established antihypertensive and was later applied to the urinary symptoms of benign prostatic enlargement and to Raynaud's phenomenon.

A distinctive second chapter in its history began when clinicians, notably Murray Raskind and colleagues at the University of Washington and the Veterans Affairs system, recognized that its ability to dampen central noradrenergic signaling could reduce the trauma-related nightmares and nighttime hyperarousal of post-traumatic stress disorder. This off-label application, supported by a series of placebo-controlled trials in veterans and soldiers, gave the old drug a prominent new role in psychiatry and sleep medicine. Now available inexpensively as a generic, prazosin is used across cardiovascular, urological, and psychiatric indications.

Prazosin is a durable and versatile medication that has earned particular respect for a use its original developers never envisioned: easing the nightmares and disrupted sleep of post-traumatic stress disorder. In that role it is one of the most studied pharmacological options, and meta-analyses of placebo-controlled trials support a meaningful benefit on nightmare frequency and intensity, especially in veterans and service members.

As an antihypertensive and as a treatment for the urinary symptoms of an enlarged prostate it remains useful and affordable. Clinicians do respect its quirks: the well-known first-dose phenomenon, an abrupt drop in blood pressure that can cause dizziness or fainting, means it is started at a low dose and titrated carefully. Taken as a whole, prazosin is an inexpensive, widely available generic with a genuinely valuable and evidence-supported place in both cardiovascular medicine and the management of trauma-related sleep disturbance.